Navigation Links
Studies explore potential origins of addiction and treatments
Date:11/12/2013

SAN DIEGO Studies released today suggest promising new treatments for nicotine and heroin addiction, and further our understanding of pathological gambling and heroin abuse in those suffering chronic pain. This new knowledge, released at Neuroscience 2013, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news about brain science and health, may one day lead to non-pharmaceutical interventions and therapies to treat addiction.

According to the World Health Organization, 15.3 million people worldwide suffer from drug use disorders. A variety of brain areas and processes play a role in addictive behaviors, complicating treatment and costing millions of dollars and lives each year. Today's studies contribute to an understanding of how compulsive disorders like addiction develop and provide new insight into methods to treat addictive behaviors .

The new findings show that:

  • Magnetic stimulation of the brain helps some people decrease their smoking, and even quit altogether for up to six months after treatment (Abraham Zangen, abstract 635.03, see attached summary).

  • Stimulating an area of the brain associated with drug reward, the subthalamic nucleus, reduces rats' motivation to take heroin (Carrie Wade, PhD, abstract 818.03, see attached summary).

  • Chronic pain leads rats already exposed to drugs to take more and higher doses of heroin, suggesting that people with addiction are more susceptible to overdose when in chronic pain (Lucia Hipolito, PhD, abstract 158.05, see attached summary).

Other recent findings discussed show that:

  • Drug abuse stresses the brain, and the resulting dysregulation of systems involved in the stress response could contribute to negative feelings that trigger increased drug taking and addiction (George Koob, PhD, presentation 689, see attached speaker summary).

  • Research suggests an area of the brain known as the insula may be overactive in people with gambling problems. People with damage to this area were less prone to the motivations of gamblers, providing a clue to identify areas of the brain that are linked to gambling addiction (Luke Clark, PhD, presentation 686.05, see attached speaker summary).

  • Pathological gamblers may love a cash payout, but care less about other types of rewards, such as sex or food. Researchers found pathological gamblers showed decreased activity in reward-sensitive brain areas when money wasn't involved (Guillaume Sescousse, PhD, presentation 686.06, see attached speaker summary).

"Non-drug interventions would be an enormous step forward in drug abuse treatment, which currently relies on replacing one drug with another and has an extremely high rate of relapse," said press conference moderator Barry Everitt of the University of Cambridge, an expert in drug abuse research. "Today's exciting results give us new ways of understanding why compulsive conditions such as drug abuse and pathological gambling might arise, and give us targets to explore for non-drug treatment, which would help us treat a population suffering from addiction."


'/>"/>

Contact: Kat Snodgrass
media@sfn.org
202-962-4090
Society for Neuroscience
Source:Eurekalert

Related medicine news :

1. Studies pinpoint specific brain areas and mechanisms associated with depression and anxiety
2. Colorado Knee Specialist Robert LaPrade, MD Publishes New Studies Covering the Function of the Posterior Cruciate Ligament (PCL) and Treatments for PCL Injuries
3. The National Cancer Institute is Presenting “Acquisition of High Quality Tissues to Support Genome Studies” at Sample Prep East in Cambridge, MA, December 9-10, 2013
4. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
5. Studies: Current hepatitis C treatments cant be used by more than half of patients; others lose opportunity for treatment
6. PolyU Advances Scientific Studies of Traditional Chinese Medicine
7. Rheumatoid arthritis and heart disease: Mayo Clinic studies shed light on dangerous connection
8. New Studies Linking Environmental Toxins to Infertility Validate Benefits of Fairhaven Health's FertileDetox
9. UCSB anthropologist studies the evolutionary benefit of human personality traits
10. For first time, drug developed based on zebrafish studies passes Phase I clinical trial
11. Sequencing studies help pinpoint gene in Prader-Willi syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... The Alliance Healthcare ... designed to further positively impact the health and wellness of our community in ... it our duty to seriously consider releasing our assets beyond our 5% targeted ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — ... Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? , The ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
(Date:2/16/2017)... ... 2017 , ... The Price Agency, a Jefferson County-based firm ... the Birmingham area, is announcing an ongoing charity event to help raise support ... son, Anius. , Anius is medically complex with diagnoses consisting and not limited ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... , February 17, 2017 According to ... Particle Counters, Liquid Particle Counters), Application (Cleanroom Monitoring, Contamination Monitoring of ... to 2021" published by MarketsandMarkets, the market is expected to reach ... at a CAGR of 3.7% from 2016 to 2021. ... ...
(Date:2/17/2017)... 17, 2017 Theravance Biopharma, Inc. (NASDAQ: ... "Company") today announced the presentation of positive clinical ... administered pan-Janus kinase (JAK) inhibitor designed to be ... of the European Crohn,s and Colitis Organization (ECCO). ... data from its completed Phase 1 study of ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Pharmaceutical Contract ... ... for the US, Canada , Japan ... Rest of World. Annual estimates and forecasts are provided for the period ... markets. Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: